Eli Lilly's newly launched obesity pill Foundayo recorded 1,390 U.S. prescriptions in the week ended April 10, following its April 1st approval. Novo Nordisk's oral Wegovy reached 113,354 prescriptions in the same week, up from 105,366 the prior week. Guggenheim analysts noted Lilly expects early prescription data volatility. Eli Lilly shares rose nearly 3% in premarket trading.
Comments